The global pediatric cancer biomarkers market size is likely to be valued at US$891.3 million in 2026, and is expected to reach US$1,682.4 million by 2033, growing at a CAGR of 9.5% during the forecast period from 2026 to 2033, driven by the increasing clinical adoption of next-generation sequencing for comprehensive pediatric tumor profiling, the FDA’s accelerated approval pathway for pediatric oncology therapies that supports biomarker-drug co-development, and the expanding use of measurable residual disease (MRD) biomarkers in pediatric leukemia management, generating recurring demand for testing throughout treatment and post-remission monitoring.

Driver - CAR-T Cell Therapy Expansion Generating CD19/CD22 Biomarker Diagnostic Requirements

The FDA’s approval of tisagenlecleucel (Kymriah, Novartis) in August 2017 as the first CAR-T cell therapy for patients up to 25 years of age with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) significantly increased demand for pediatric oncology biomarker testing. As Kymriah requires confirmed CD19 expression before treatment, CD19 immunophenotyping using flow cytometry has become a standard diagnostic requirement for eligible B-ALL patients.

In addition, therapies such as loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics), which also require CD19 confirmation, along with the ongoing development of CD22-targeted CAR-T and antibody-drug conjugate (ADC) therapies for relapsed B-ALL, are further driving demand for CD19 and CD22 biomarker testing in pediatric oncology.

Restraint - Limited Pediatric Tumor Tissue Availability for Biomarker Profiling

Comprehensive genomic biomarker profiling in pediatric tumors is often limited by the small tissue samples obtained from biopsies, particularly in young children with solid tumors such as neuroblastoma, hepatoblastoma, and medulloblastoma. These limited specimens frequently fail to meet the minimum tumor cellularity and DNA input requirements needed for next-generation sequencing (NGS)-based comprehensive genomic profiling.

This limitation places a structural cap on tissue-based pediatric biomarker testing volumes and has accelerated interest in liquid biopsy approaches. Cell-free DNA (cfDNA) levels in pediatric cancer patients are often lower than those observed in adults with similar disease burden, reducing liquid biopsy sensitivity and posing analytical challenges for circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) monitoring across certain pediatric tumor types.

Opportunity - Liquid Biopsy and Cell-Free DNA for Pediatric Neuroblastoma Monitoring

Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8-10% of childhood cancers and nearly 15% of pediatric cancer deaths in the U.S. The disease presents a strong opportunity for liquid biopsy-based biomarker monitoring because neuroblastoma cells release circulating tumor DNA (ctDNA), including MYCN-amplified DNA fragments, into the bloodstream. This enables non-invasive monitoring of tumor burden and reduces the need for repeated invasive biopsies in young children.

The NCI’s TARGET (Therapeutically Applicable Research to Generate Effective Treatments) Neuroblastoma project has generated extensive genomic data sets for pediatric neuroblastoma. The program identified clinically relevant biomarkers, including ALK mutations, MYCN amplification, PHOX2B mutations, and segmental chromosomal aberrations. Serial monitoring of these biomarkers during treatment can support adaptive therapy decisions.

Product Type Insights

CD19 is anticipated to dominate the product type segment, accounting for approximately 28% of the total revenue in 2026. Growth is driven by the widespread use of CD19 in diagnosing and treating B-cell malignancies. Increasing adoption of CD19-targeted immunotherapies, particularly CAR-T cell therapies for leukemia and lymphoma, further supports demand. Novartis developed Kymriah (tisagenlecleucel), a CD19-targeted CAR-T therapy approved for B-cell acute lymphoblastic leukemia (ALL) and certain lymphomas.

ALK is expected to be the fastest-growing product type. Increasing ALK biomarker testing is improving the diagnosis and treatment of pediatric cancers such as neuroblastoma, anaplastic large cell lymphoma (ALCL), and inflammatory myofibroblastic tumors (IMTs). Growing adoption of precision oncology, expanded molecular profiling, and the availability of ALK-targeted therapies are supporting demand for ALK testing.

Indication Insights

Leukemia is expected to dominate the indication, holding approximately 40% of the total revenue in 2026, propelled by extensive use of biomarker testing and targeted therapies in disease diagnosis and treatment selection. High prevalence of hematologic malignancies and the growing adoption of precision medicine approaches continue to drive testing demand. St. Jude Children’s Research Hospital uses genomic and biomarker testing, including MRD monitoring, to guide diagnosis and treatment decisions in pediatric leukemia, especially ALL.

Neuroblastoma is likely to be the fastest-growing indication, fueled by the increasing adoption of biomarker-guided therapies and precision medicine approaches in pediatric oncology. Growing research efforts and clinical trials focused on targeted treatments are expanding the use of advanced diagnostic testing in neuroblastoma patients. Children’s Hospital of Philadelphia (CHOP) conducts neuroblastoma research using biomarker-driven genomic profiling, including MYCN and ALK testing, to support risk stratification and targeted therapy selection.

End-user Insights

Hospitals are projected to dominate, holding approximately 46% of the total revenue in 2026, due to their role as primary centers for cancer diagnosis, biomarker testing, and treatment administration. They possess advanced laboratory infrastructure, multidisciplinary oncology teams, and access to specialized diagnostic technologies. Fortis Cancer Institute integrates advanced molecular and biomarker testing, next-generation sequencing (NGS), multidisciplinary tumor boards, and targeted therapy selection within a hospital setting.

Oncology centers are likely to be the fastest-growing end-user segment, due to their increasing specialization in cancer diagnosis, molecular profiling, and targeted treatment planning. The rising adoption of precision oncology and companion diagnostic testing is driving higher patient volumes to these dedicated centers. Memorial Sloan Kettering Cancer Center (MSKCC), a leading dedicated oncology center that extensively uses molecular profiling, NGS-based tumor testing, and companion diagnostics to guide precision oncology treatment decisions.

North America Pediatric Cancer Biomarkers Market Trends

North America is projected to dominate, accounting for approximately 42% of the global revenue share in 2026. The region's dominance is driven by its advanced pediatric oncology research and clinical infrastructure. The FDA's RACE for Children Act has strengthened pediatric biomarker co-development programs, while the Children's Oncology Group (COG) network of more than 220 institutions across North America supports a high volume of pediatric cancer biomarker clinical trials.

U.S. Pediatric Cancer Biomarkers Market Trends

The U.S. is estimated to account for approximately 88% of North America's revenue in 2026. The American Cancer Society estimates approximately 9,680 new cancer diagnoses in U.S. children under 15 annually, with leukemia (29%), brain and CNS tumors (26%), and neuroblastoma (7%) representing the three highest-incidence pediatric cancer categories.

Canada Pediatric Cancer Biomarkers Market Trends

Canada is forecast to account for approximately 12% of North America's pediatric cancer market revenue in 2026. Market growth is supported by Canada's publicly funded pediatric oncology network, increasing investment in childhood cancer research, and expanding access to precision medicine and advanced therapies. The country's Cancer in Young People in Canada (CYP-C) program strengthens nationwide surveillance and supports evidence-based treatment planning, while more than 86% of children survive at least five years after diagnosis, reflecting continued improvements in pediatric cancer care.

Europe Pediatric Cancer Biomarkers Market Trends

Europe is estimated to hold approximately 27% of the global market revenue in 2026. Europe’s well-established pediatric oncology cooperative group network, including SIOPE (European Society for Paediatric Oncology) coordinating pan-European pediatric cancer clinical trials with integrated biomarker testing protocols, and the EMA’s Paediatric Investigation Plan (PIP) requirement paralleling the U.S. RACE Act in mandating pediatric oncology drug studies, create a structurally supportive regulatory and clinical research environment for pediatric biomarker market development.

Germany Pediatric Cancer Biomarkers Market Trends

Germany is expected to account for approximately 24% of Europe revenue in 2026, driven by its large and highly developed healthcare infrastructure. The country benefits from substantial healthcare spending, strong reimbursement systems, and widespread adoption of advanced medical technologies. Germany is a major hub for medical device manufacturing, biotechnology, and clinical research activities across Europe.

U.K. Pediatric Cancer Biomarkers Market Trends

The U.K. market is expected to hold approximately 20% of market share in 2026, fueled by its well-established healthcare system and high adoption of advanced medical technologies. Strong investments in clinical research, diagnostics, and specialized healthcare services support market growth. The country benefits from a robust regulatory framework and the presence of leading healthcare and life sciences organizations.

Asia Pacific Pediatric Cancer Biomarkers Market Trends

Asia Pacific is likely to be the fastest-growing regional market, projected to expand at a CAGR of approximately 11.6% from 2026 to 2033. GLOBOCAN 2022 data indicates that Asia carries the highest global absolute burden of pediatric cancer incidence, driven by population size and the high absolute birth rates generating large at-risk pediatric populations, with below-average current diagnostic penetration representing the most significant expansion opportunity in the global market.

China Pediatric Cancer Biomarkers Market Trends

China is estimated to command approximately 36% of Asia Pacific revenue in 2026. The National Cancer Center of China documents approximately 32,792 annual new pediatric cancer cases in China, the world’s highest absolute pediatric cancer incidence by country, with leukemia representing the predominant cancer type driving CD19 immunophenotyping and MRD monitoring demand across China’s expanding children’s hospital oncology department network.

India Pediatric Cancer Biomarkers Market Trends

India is projected to account for approximately 21% of Asia Pacific revenue in 2026 due to its large patient population and rapidly expanding healthcare infrastructure. Growth is driven by increasing healthcare expenditure, rising awareness and adoption of advanced diagnostic and therapeutic technologies, increasing incidence of pediatric cancers, expanding molecular diagnostics infrastructure, and improving access to precision oncology.

The global pediatric cancer biomarkers market is characterized by the presence of leading life sciences and in vitro diagnostics companies, specialized molecular diagnostics providers, and genomics technology firms offering comprehensive solutions for pediatric oncology biomarker testing. These companies compete through advanced molecular diagnostic platforms, immunohistochemistry systems, flow cytometry technologies, and next-generation sequencing (NGS) solutions that support biomarker discovery, diagnosis, treatment selection, and disease monitoring across pediatric cancers.

Roche Diagnostics maintains a strong position in the market with an integrated portfolio that includes flow cytometry reagents for CD19, CD20, and CD22 immunophenotyping, VENTANA immunohistochemistry platforms for ALK detection, cobas molecular diagnostics systems for BCR-ABL1 measurable residual disease (MRD) monitoring, and the FoundationOne CDx platform through its Foundation Medicine subsidiary. Thermo Fisher Scientific is another prominent player, supporting pediatric oncology through its Ion Torrent Oncomine Comprehensive Assay used in the NCI Pediatric MATCH trial, alongside an extensive portfolio of flow cytometry reagents, PCR solutions, and cell-free DNA library preparation kits that facilitate MRD assessment, liquid biopsy testing, and comprehensive pediatric tumor profiling.

Key Industry Developments:

• In August 2024, Illumina announced that the U.S. FDA approved its TruSight Oncology Comprehensive (TSO Comprehensive) test, the first distributable comprehensive genomic profiling in vitro diagnostic kit with pan-cancer companion diagnostic claims. The test analyzed more than 500 genes and enabled clinicians to identify actionable biomarkers and match cancer patients to targeted therapies more efficiently. The FDA also approved two companion diagnostic indications, including detection of NTRK gene fusions in adult and pediatric solid tumors and RET fusions in non-small cell lung cancer.
• In July 2024, Thermo Fisher Scientific partnered with the U.S. National Cancer Institute (NCI) on the myeloMATCH precision medicine umbrella trial to advance research in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). The company used its next-generation sequencing (NGS) technology to analyze patients’ bone marrow and blood samples for key genetic biomarkers. This approach enabled clinical sites to identify eligible patients more rapidly and match them with clinical trials evaluating targeted therapies for specific mutations.